<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
Lovastatin is a lipid-lowering drug used to reduce the risk of cardiovascular disease. Lovastatin shows poor oral bioavailability (<5%) because of its low water solubility and short half-life. Therefore, the present study was performed to determine the effects of the Trivedi Effect®- Consciousness Energy Treatment (Blessing) on lovastatin and rats through the measurement of plasma lovastatin hydroxy acid concentrations after the oral administration of lovastatin in rats. The test item, lovastatin was divided into two parts. One part was denoted as the control, while the other part was defined as the Biofield Energy Treated sample, which received the Biofield Energy Treatment for about 3 minutes by renowned Biofield Energy Healer, Dahryn Trivedi. Additionally, one group of animals also received Biofield Energy Treatment under similar conditions. The BiofieldEnergy Healer who was located in the USA, while the test samples and animals were located in the research laboratory in India. Lovastatin oral formulations were administrated by oral gavage at a dose of 50 mg/kg in groups viz. G1 (untreated lovastatin), G2 (Biofield Treated lovastatin), and G3 (Biofield Treated animals received untreated lovastatin) group. The majority of lovastatin was rapidly converted to its metabolite, i.e., lovastatin hydroxy acid following the oral administration. The pharmacokinetic parameter, the Cmax of lovastatin hydroxy acid was significantly altered by 155.76% and -24.82% in G2 and G3, respectively compared to G1. The Tmax of lovastatin hydroxy acid was significantly increased by 254.55% in G2 and 51.52% in G3 compared to G1. The mean residence time of lovastatin hydroxy acid was also altered in G2 (-30.46%) and G3 (3.96%), as compared to the G1. The relative oral bioavailability (Fr) of lovastatin was significantly increased by 281.87% in the group G2 and 15.71% in the group G3 compared to the G1. These data suggest that the Biofield Energy Treatment could be considered as an innovative strategy that opens new avenues to improve the bioavailability of nutraceuticals/pharmaceuticals and can also modulate thetherapeutic performance of orally active molecules. The Biofield Energy Treated lovastatin could be beneficial for the treatment of cardiovascular disease, which includes heart attack, stroke, atherosclerosis, coronary revascularization, coronary death, myocardial infarction, unstable angina, peripheral artery disease, abdominal aortic aneurysm, chronic kidney disease, etc. Lovastatin Journal Web URL:- https://medwinpublishers.com/BEBA/volume.php?volumeId=397&issueId=1142
Bioavailability, Biofield Energy Treatment, Rat, Pharmacokinetics, LC-MS-MS, Lovastatin, Lovastatin Hydroxy Acid
Bioavailability, Biofield Energy Treatment, Rat, Pharmacokinetics, LC-MS-MS, Lovastatin, Lovastatin Hydroxy Acid
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |